News coverage about GTx (NASDAQ:GTXI) has been trending positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GTx earned a news impact score of 0.33 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 62 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the company’s share price in the near future.
Separately, ValuEngine cut shares of GTx from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 11th.
Shares of GTx (GTXI) traded down 1.60% during midday trading on Monday, reaching $5.54. 29,318 shares of the company were exchanged. GTx has a 52-week low of $2.73 and a 52-week high of $11.19. The company’s market capitalization is $88.87 million. The stock’s 50-day moving average price is $4.22 and its 200-day moving average price is $4.94.
GTx (NASDAQ:GTXI) last posted its quarterly earnings data on Monday, May 15th. The biopharmaceutical company reported ($0.39) EPS for the quarter. Analysts anticipate that GTx will post ($1.16) EPS for the current year.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.